ACADVL: A Protein Implicated in Various Diseases (G37)

Target Name: ACADVL

NCBI ID: G37

ACADVL

Other Name(s): ACADVL variant 1 | Acyl-Coenzyme A dehydrogenase, very long chain | Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (isoform 2) | acyl-CoA dehydrogenase very long chain | Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (isoform 3) | ACAD6 | Very long-chain specific acyl-CoA dehydrogenase, mitochondrial | ACADVL variant 2 | Acyl-CoA dehydrogenase very long chain, transcript variant 2 | Acyl-CoA dehydrogenase very long chain, transcript variant 3 | Acyl-Coenzyme A dehydrogenase, very long chain (isoform 1) | VLCAD | ACADV_HUMAN | Acyl-CoA dehydrogenase very long chain, transcript variant 1 | Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (isoform 1) | LCACD | ACADVL variant 3 | acyl-Coenzyme A dehydrogenase, very long chain

ACADVL: A Protein Implicated in Various Diseases

Acadolipin (ACADVL) is a protein that is expressed in various tissues throughout the body. It is a constituent of the cell membrane and plays a vital role in maintaining the structural integrity of the cell membrane. It is also involved in the regulation of lipid metabolism and has been implicated in the development and progression of various diseases. In this article, we will discuss ACADVL as a drug target and its potential as a biomarker for various diseases.

Diseases associated with ACADVL

Several diseases have been associated with ACADVL. The most significant of these is the development of cardiovascular diseases. The increased levels of ACADVL in the blood vessels of individuals with heart disease can lead to the formation of plaque, which can cause the blockage of blood flow and contribute to the development of heart failure and other cardiovascular diseases.

Another disease associated with ACADVL is the development of certain types of cancer. Studies have shown that ACADVL is expressed in various types of cancer, including breast, ovarian, and prostate cancer. The presence of ACADVL has been linked to the development of cancer cell invasion and metastasis.

In addition to these diseases, ACADVL has also been linked to the development of other conditions such as obesity, diabetes, and neurodegenerative disorders. These conditions have been associated with the increased levels of ACADVL in various tissues and cells.

ACADVL as a drug target

The potential of ACADVL as a drug target comes from its involvement in various cellular processes that are associated with the development of many diseases. One of the primary targets of ACADVL is the regulation of lipid metabolism. Lipid metabolism is the process by which the body produces and uses energy and regulates the levels of different types of lipids, including cholesterol and triglycerides.

ACADVL is involved in the regulation of lipid metabolism by several mechanisms. Firstly, it can inhibit the production of low-density lipoprotein (LDL) cholesterol, which is a major risk factor for the development of cardiovascular diseases. Secondly, it can increase the production of high-density lipoprotein (HDL) cholesterol, which is associated with a lower risk of cardiovascular disease.

In addition to its role in lipid metabolism, ACADVL has also been shown to play a role in the regulation of cellular signaling processes. It is involved in the regulation of several signaling pathways that are involved in cell growth, differentiation, and survival.

ACADVL as a biomarker

The potential of ACADVL as a biomarker for various diseases comes from its expression in various tissues and cells. Several studies have shown that ACADVL is expressed in a variety of tissues and cells, including blood vessels, cancer cells, and nerve cells. This makes it a potential biomarker for a range of diseases.

One of the primary applications of ACADVL as a biomarker is its potential to be used as a diagnostic marker for cardiovascular diseases. The increased levels of ACADVL in the blood vessels of individuals with heart disease can be used as a diagnostic indicator of the development of cardiovascular disease.

In addition to its potential as a diagnostic marker, ACADVL has also been shown to be an attractive biomarker for cancer. The increased levels of ACADVL in various types of cancer cells can be used as a diagnostic indicator of the presence of cancer.

Another application of ACADVL as a biomarker is its potential to be used as a therapeutic target for diseases associated with high levels of ACADVL, such as cancer. By inhibiting the production of ACADVL or increasing the degradation of ACADVL, it may be possible to reduce the levels of ACADVL in various tissues and cells and improve the health of individuals with these diseases.

Conclusion

In conclusion, ACADVL is a protein that is expressed in various tissues throughout the body and is involved in the regulation of various cellular processes that are associated with the development of many diseases. Its potential as a drug target and biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of ACADVL in

Protein Name: Acyl-CoA Dehydrogenase Very Long Chain

Functions: Very long-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation, an aerobic process breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (PubMed:7668252, PubMed:9461620, PubMed:18227065, PubMed:9839948, PubMed:9599005). The first step of fatty acid beta-oxidation consists in the removal of one hydrogen from C-2 and C-3 of the straight-chain fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl-CoA (PubMed:7668252, PubMed:9461620, PubMed:18227065, PubMed:9839948). Among the different mitochondrial acyl-CoA dehydrogenases, very long-chain specific acyl-CoA dehydrogenase acts specifically on acyl-CoAs with saturated 12 to 24 carbons long primary chains (PubMed:21237683, PubMed:9839948)

The "ACADVL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACADVL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets